UCB, Cancer Research UK and Cancer Research Horizons have announced a new strategic alliance aimed at accelerating the development of novel cancer therapies. The collaboration will combine UCB’s expertise in antibody discovery and drug development with Cancer Research UK’s translational research capabilities and Cancer Research Horizons’ oncology innovation network.

The partnership is designed to speed the progression of promising oncology assets from early discovery through to clinical development, with a focus on delivering innovative targeted therapies for patients with high unmet medical need. By bringing together scientific, clinical and commercial expertise, the organisations aim to strengthen the translation of cutting-edge cancer research into potential new medicines.

Cancer Research Horizons, the innovation arm of Cancer Research UK, will provide access to its drug discovery platforms, translational infrastructure and extensive oncology network. UCB will contribute its biologics and immunology capabilities to support the advancement of next-generation cancer therapeutics.

The alliance reflects growing collaboration between biopharma companies and cancer research organisations to accelerate innovation and improve outcomes for patients. The partners said the agreement reinforces their shared commitment to advancing breakthrough science and expanding treatment options across oncology.